Clinical Trial on the Efficacy of a New Symbiotic Formulation, Flortec, in Patients With Irritable Bowel Syndrome: A Multicenter, Randomized Study
The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Efficacy of symbiotics in patients with irritable bowel syndrome (IBS) remains unknown. METHODS: Patients were randomized to a prebiotic (n=135), or a symbiotic formulation containing Lactobacillus paracasei B21060 (Flortec, n=132). Primary efficacy was the responder rate for pain and global relief of symptoms in the overall population and in patients with predominant diarrhea (n=47). Post hoc time-trend analyses for changes within each treatment were carried out. RESULTS: Patients with absent/mild pain amounted to 54.7% in the symbiotic group and to 57.4% in the prebiotic group at treatment week 4, and to 53.9% and 53.4% at the end of treatment. Patients with amelioration of well-being were, respectively, 60.7% versus 61.7% at treatment week 4, and 63.3% versus 60.9% at the end of treatment. Within each treatment group, patients with absent/mild pain increased in the Flortec and the prebiotic group, but time trend analyses were significant only for Flortec (P=0.019). In IBS-predominant diarrhea, Flortec significantly reduced bowel movements, pain, and IBS scores. CONCLUSIONS: To improve pain and well-being, Flortec is encouraging in patients with diarrhea predominant IBS. To establish its efficacy for the majority of IBS patients, Flortec has to be compared with an inert placebo in future work.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With regard to synbiotics, there are some studies but their design is not sufficiently robust to draw any firm conclusions251–255 although the concept of combining a prebiotic and probiotic is theoretically attractive.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [251]
Citations
Cites
Dietary modulation of the human colonic microbiota: updating the concept of prebiotics
Gibson, G. R., Probert, H. M., Loo, J. V., Rastall, R. A., & Roberfroid, M. B. (2004) · Nutrition Research Reviews · doi:10.1079/nrr200479 · Cited by 2,536 · cited 1×
“As shown in human studies, supplementation with fructose-oligosaccharides leads to considerable changes in the composition of the fecal flora.(16,17) This would mean that in our study the placebo was not inert but acted as a prebiotic.”
ResultFunctional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Postinfectious Irritable Bowel Syndrome
Spiller, R., & Garsed, K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.074 · Cited by 1,024
Activation of the mucosal immune system in irritable bowel syndrome
Chadwick, V. S., Chen, W., Shu, D., Paulus, B., Bethwaite, P., Tie, A., & Wilson, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.33579 · Cited by 833
Malinen, E., Rinttila, T., Kajander, K., Matto, J., Kassinen, A., Krogius, L., Saarela, M., Korpela, R., & Palva, A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40312.x · Cited by 699
Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis
D'Souza, A. L., Rajkumar, C., Cooke, J., & Bulpitt, C. J. (2002) · BMJ · doi:10.1136/bmj.324.7350.1361 · Cited by 664 · cited 1×
“Lactobacilli are considered to be safe for healthy and immunosuppressed individuals.(20,21) Twenty-five subjects in the symbiotic group and 30 in the placebo had symptoms worsened during the study, but only 5 and 4 subjects, respectively, withdrew from the study because of adverse effects.”
BackgroundSafety of Probiotics That Contain Lactobacilli or Bifidobacteria
Borriello, S. P., Hammes, W. P., Holzapfel, W., Marteau, P., Schrezenmeir, J., Vaara, M., & Valtonen, V. (2003) · Clinical Infectious Diseases · doi:10.1086/368080 · Cited by 551 · cited 1×
“Lactobacilli are considered to be safe for healthy and immunosuppressed individuals.(20,21) Twenty-five subjects in the symbiotic group and 30 in the placebo had symptoms worsened during the study, but only 5 and 4 subjects, respectively, withdrew from the study because of adverse effects.”
BackgroundDesign of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Onset and Disappearance of Gastrointestinal Symptoms and Functional Gastrointestinal Disorders
Talley, N. J., Weaver, A. L., Zinsmeister, A. R., & Melton, L. J. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116483 · Cited by 475 · cited 1×
“As shown in human studies, supplementation with fructose-oligosaccharides leads to considerable changes in the composition of the fecal flora.(16,17) This would mean that in our study the placebo was not inert but acted as a prebiotic.”
ResultMeta‐analysis: the effect of probiotic administration on antibiotic‐associated diarrhoea
Cremonini, F., Di Caro, S., Nista, E. C., Bartolozzi, F., Capelli, G., Gasbarrini, G., & Gasbarrini, A. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01318.x · Cited by 384
Cited by
Swanson, K. S., Gibson, G. R., Hutkins, R., Reimer, R. A., Reid, G., Verbeke, K., Scott, K. P., Holscher, H. D., Azad, M. B., Delzenne, N. M., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0344-2 · Cited by 2,196
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 645
Preidis, G. A., & Versalovic, J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.072 · Cited by 485
Diagnosis and Treatment of Irritable Bowel Syndrome: A Review
Camilleri, M. (2021) · JAMA · doi:10.1001/jama.2020.22532 · Cited by 362
Metadata
- Authors
- Andriulli, A., Neri, M., Loguercio, C., Terreni, N., Merla, A., Cardarella, M. P., Federico, A., Chilovi, F., Milandri, G. L., De Bona, M., Cavenati, S., Gullini, S., Abbiati, R., Garbagna, N., Cerutti, R., & Grossi, E.
- Affiliations
- Casa Sollievo della Sofferenza (IT)
- University of Chieti-Pescara (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Ospedale Valduce (IT)
- Ospedale di Bolzano (IT)
- Ospedale “M. Bufalini” di Cesena (IT)
- Corresponding author
- Andriulli, Angelo
- Merla, Antonio
- Cavenati, Sergio
- ORCID
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2008-09
- Volume
- 42
- Issue
- Supplement 3
- Pages
- S218-S223
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2031153328
- Cited by
- 75
- References
- 25
- Citations by year
- 2025: 1 · 2024: 6 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 5 · 2015: 5 · 2014: 9 · 2013: 2 · 2012: 8
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- irritable bowel syndrome, symbiotics, prebiotics, Lactobacillus paracasei, abdominal pain, well-being, defecation, probiotics
- MeSH terms
- Adult, Double-Blind Method, Drug Synergism, Female, Glutamine, Humans, Lactobacillus, Male, Middle Aged, Oligosaccharides, Treatment Outcome, Probiotics, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Trial on the Efficacy of a New Symbiotic Formulation, Flortec, in Patients With Irritable Bowel Syndrome: A Multicenter, Randomized Study. https://app.cochat.ai/papers/10.1097/mcg.0b013e31817fadd6
- The paper
- Andriulli, A., Neri, M., Loguercio, C., Terreni, N., Merla, A., Cardarella, M. P., Federico, A., Chilovi, F., Milandri, G. L., De Bona, M., Cavenati, S., Gullini, S., Abbiati, R., Garbagna, N., Cerutti, R., & Grossi, E. (2008). Clinical Trial on the Efficacy of a New Symbiotic Formulation, Flortec, in Patients With Irritable Bowel Syndrome: A Multicenter, Randomized Study. Journal of Clinical Gastroenterology. https://doi.org/10.1097/mcg.0b013e31817fadd6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.